Cipla Ltd Share Price

Overview

Cipla Ltd share price is currently ₹1,418.82, up by ₹18.35 (1.31%) from its previous closing price of ₹1,400.47. The share price has gained 0.95% over the past month and declined -6.29% over the past year. The stock's 52-week low and high are ₹1,146.55 and ₹1,652.66, respectively. Cipla Ltd has a market capitalisation of ₹ 1,20,000.00 Cr. The share price was last updated on 20 Aug 2026, 03:56 PM IST.

Cipla Ltd

CIPLA

₹0.00

₹18.35

1.31%

Healthcare

₹0.00(%)1D

Updated: 20 Aug 2026, 03:56:06 pm IST

Market Data

Open Price

₹1,410.43

Prev. Close

₹1,400.47

₹1,407.89

Day Low

₹1,420.30

Day High

₹1,146.55

52 Week Low

₹1,652.66

52 Week High

HealthcarePharmaceuticals & Drugs

CategoryLarge Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

34.00

Sector PE

42.16

PB Ratio

3.33

Sector PB

5.82

EPS

41.73

Dividend Yield

1.06

Today's Volume

326.906 K

5 Day Avg. Volume

577.371 K

PEG Ratio

-1.29

Market Cap.

₹ 1,20,000.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 650% at ₹13/Share	05-Jun-2026	05-Jun-2026
DividendsSpecial Dividend of 150% at ₹3/Share	27-Jun-2025	27-Jun-2025
DividendsFinal Dividend of 650% at ₹13/Share	27-Jun-2025	27-Jun-2025

Mutual Fund Ownership

Mutual Fund Holder	Jun 26 Shares held	Jul 26 Shares held
HDFC Flexi Cap Fund - Growth	2.03 Cr	1.99 Cr (2.12%)
Parag Parikh Flexi Cap Fund - Regular Plan - Growth	1.44 Cr	1.44 Cr no change
SBI Nifty 50 ETF	1.08 Cr	1.09 Cr (0.72%)
ICICI Prudential Value Fund - Growth	55.49 Lac	55.49 Lac no change
HDFC Focused Fund - Regular Plan - Growth	69.52 Lac	50.97 Lac (26.69%)

Show all holdings

About Cipla Ltd 👋

Cipla Limited is an India-based global pharmaceutical company. The Company is engaged in manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). Its geographical segments include India, the United States, South Africa, and the Rest of the World. It has its network of manufacturing, trading and other incidental operations in India and International markets.